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Herpes simplex virus type 1 
epidemiology in the Middle east 
and North Africa: systematic 
review, meta-analyses, and meta-
regressions
sonia Chaabane1, Manale Harfouche1, Hiam Chemaitelly  1, Guido schwarzer  2 & 
Laith J. Abu-Raddad  1,3,4
This study aimed at characterizing herpes simplex virus type 1 (HSV-1) epidemiology in the Middle 
East and North Africa (MENA). HSV-1 records were systematically reviewed. Findings were reported 
following the PRISMA guidelines. Random-effects meta-analyses were implemented to estimate 
pooled mean HSV-1 seroprevalence. Random-effects meta-regressions were conducted to identify 
predictors of higher seroprevalence. Thirty-nine overall seroprevalence measures yielding 85 stratified 
measures were identified and included in the analyses. Pooled mean seroprevalence was 65.2% (95% 
CI: 53.6–76.1%) in children, and 91.5% (95% CI: 89.4–93.5%) in adults. By age group, seroprevalence 
was lowest at 60.5% (95% CI: 48.1–72.3%) in <10 years old, followed by 85.6% (95% CI: 80.5–90.1%) 
in 10–19 years old, 90.7% (95% CI: 84.7–95.5%) in 20–29 years old, and 94.3% (95% CI: 89.5–97.9%) in 
≥30 years old. Age was the strongest predictor of seroprevalence explaining 44.3% of the variation. 
Assay type, sex, population type, year of data collection, year of publication, sample size, and sampling 
method were not significantly associated with seroprevalence. The a priori considered factors explained 
48.6% of the variation in seroprevalence. HSV-1 seroprevalence persists at high levels in MENA with 
most infections acquired in childhood. there is no evidence for declines in seroprevalence despite 
improving socio-economic conditions.
Herpes simplex virus type 1 (HSV-1) is a widespread and incurable infection1,2. Although this infection is usually 
asymptomatic3, the virus is shed frequently and subclinically4,5. Clinically-apparent HSV-1 infection most often 
manifests as orolabial herpes lesions6,7, but the virus causes a diverse spectrum of diseases including neonatal 
herpes, corneal blindness, herpetic whitlow, meningitis, encephalitis, and genital herpes7,8. The infection’s clinical 
manifestations depend on the virus’ initial acquisition portal6,7—oral-to-oral transmission leads to an oral infec-
tion6,7, and oral-to-genital transmission (through oral sex) leads to a genital infection6,9,10.
HSV-1 is endemic globally as indicated by the high HSV-1 antibody prevalence (seroprevalence) across 
regions2,11,12. Although HSV-1 is typically acquired in childhood8, changes in hygiene and socio-economic condi-
tions appear to have reduced exposure during childhood in Western11,13–20 and Asian countries21. A large fraction 
of youth in these countries reach sexual debut with no protective antibodies against HSV-1 infection, and thus 
at risk of acquiring the infection genitally6,22. A growing evidence indicates that HSV-1 is overtaking HSV-2 as 
the leading cause of first episode genital herpes in Western6,22–26 and (apparently) Asian countries21. The extent to 
which such a transition in HSV-1 epidemiology is occurring in other global regions remains unknown.
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In this context, we aspired to determine HSV-1 seroprevalence levels in the Middle East and North Africa 
(MENA), and to characterize the extent to which HSV-1 is the etiological cause of clinically-diagnosed genital 
ulcer disease (GUD) and clinically-diagnosed genital herpes. These aims were addressed by: (1) systematically 
reviewing and synthesizing available data on HSV-1 seroprevalence and HSV-1 viral detection in GUD and geni-
tal herpes, (2) estimating the pooled mean HSV-1 seroprevalence in different populations and across ages, and (3) 
assessing the associations and predictors of higher seroprevalence and sources of between-study heterogeneity.
This study is part of a series of ongoing investigations meant to inform efforts by the World Health 
Organization (WHO) and global partners to characterize the regional and global infection and disease burden 
of HSV infections, accelerate HSV vaccine development27,28, and explore optimal strategies for HSV-1 control.
Methods
The methodology used in this study follows and adapts that used in a systematic review of HSV-1 seroprevalence 
and HSV-1 viral detection in GUD and genital herpes in Asia21.
Data sources and search strategy. The present systematic review was informed by the Cochrane 
Collaboration handbook29, and was reported following the Preferred Reporting Items for Systematic Reviews and 
Meta-analyses (PRISMA) guidelines30. The PRISMA checklist can be found in Supplementary Table S1.
A systematic literature search was conducted up to October 8, 2017, in PubMed and Embase. The search 
criteria included exploded MeSH/Emtree terms to cover all subheadings, with no language or time restric-
tions. Another search was conducted up to December 1, 2017 in national and regional databases including: 
Index Medicus for the Eastern Mediterranean Region, Iraqi Academic Scientific Journals Database, Scientific 
Information Database of Iran, and PakMediNet of Pakistan. Search strategies can be found in Supplementary 
Box S1.
The MENA region definition included 23 countries: Afghanistan, Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, 
Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Pakistan, Palestine, Qatar, Saudi Arabia, Somalia, Sudan, Syria, 
Tunisia, the United Arab Emirates (UAE), and Yemen.
study selection and inclusion and exclusion criteria. Search results were imported into Endnote, 
where duplicate records were removed. Titles and abstracts of remaining records were screened independently 
by SC, MH, and HC, for relevance. Full texts of records deemed relevant or potentially relevant were retrieved 
for further screening. Bibliographies of relevant records and reviews were also screened for possible missing 
publications.
The inclusion criteria included any record reporting an HSV-1 seroprevalence measure, based on primary data 
and type-specific diagnostic assay such as glycoprotein-G-based enzyme-linked immunosorbent assays (ELISA).
The inclusion criteria also included any record reporting a proportion of HSV-1 viral detection in 
clinically-diagnosed GUD or in clinically-diagnosed genital herpes. The minimum sample size of included stud-
ies was 10, regardless of the outcome measure.
The exclusion criteria included case reports, case series, reviews, editorials, letters to editors, commentaries, 
qualitative studies, and animal studies. HSV-1 seroprevalence measures reported in <3 months-old infants were 
excluded since they may reflect maternal antibodies.
In this work, a “record” refers to a document (a publication) reporting an outcome measure of interest, while 
a “study” refers to the details pertaining to a specific outcome measure. Accordingly, one record may contribute 
multiple studies, and multiple records of the same study are considered as duplicates and only included once.
Data extraction and data synthesis. The extracted information included: author(s), publication title, 
year(s) of data collection, publication year, country of origin, country of survey, city, study site, study design, 
study sampling procedure, study population and its characteristics (e.g., sex and age), sample size, HSV-1 out-
come measures, and diagnostic assay. Data were double extracted from relevant records by SC, MH, and HC.
Extracted outcome measures were based on their stratification in the original record. Stratifications of sero-
prevalence measures were considered using a pre-defined sequential order that prioritizes first population type, 
followed by age bracket, and then age group. Age bracket included children (<15 years of age) and adults (≥15 
years of age). Age groups included <10, 10–19, 20–29, and ≥30 years of age—a stratification informed by the 
actual available data of age-strata.
The extracted seroprevalence data were synthesized by population type according to the following definitions:
 1. Healthy general populations encompassing groups of presumably healthy persons (for example, pregnant 
women or blood donors) and outpatients attending a healthcare facility for an inconsequential health 
condition.
 2. Clinical populations encompassing any population with a serious clinical condition, or with a condition 
potentially related to a clinical manifestation of HSV-1 infection.
 3. Other populations encompassing populations not fitting the above definitions, or populations with an 
unclear risk of having acquired HSV-1, such as sex workers and mixed health-status populations.
Meta-analyses. Random-effects meta-analyses were conducted to estimate the pooled mean HSV-1 sero-
prevalence in MENA by population type, age bracket, and age group. Pooled means were calculated using 
DerSimonian-Laird random-effects models31 whenever ≥3 measures were available. The variance of the sero-
prevalence measures was stabilized using the Freeman-Tukey type arcsine square-root transformation32.
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Cochran’s Q statistic was calculated to test for heterogeneity in the pooled seroprevalence measures33,34. I2 
measure was calculated to assess the magnitude of between-study variation that is due to true variation in sero-
prevalence across studies rather than chance33. Prediction interval was estimated to characterize the heterogeneity 
in the seroprevalence measures33.
Sensitivity analyses were conducted using generalized linear mixed models (GLMM)35. The results were used 
to confirm the pooled mean HSV-1 seroprevalence estimates generated based on the Freeman-Tukey type arcsine 
square-root transformation, given a recently-identified potential pathology in this transformation35.
Meta-analyses were performed in R version 3.4.136 using the meta package37.
Meta-regressions. Univariable and multivariable random-effects meta-regression analyses, using 
log-transformed proportions, were conducted to identify associations and predictors of higher HSV-1 seroprev-
alence and sources of between-study heterogeneity. Associations were described using relative risks (RRs), 95% 
confidence intervals (CIs), and p-values.
Potential predictors were specified a priori and included: age bracket, age group, assay type, country’s 
income, population type, sample size (<100 versus ≥100), sampling method (probability-based sampling versus 
non-probability-based sampling), year of data collection, and year of publication. Factors with p-value < 0.1 in 
univariable analysis were eligible for inclusion in the multivariable model. Factors with p-value < 0.05 in the mul-
tivariable analysis were considered as statistically significant predictors.
Assay type consisted of five assay types for which data were available: ELISA, enzyme immunoassay (EIA), 
immunofluorescence assay (IFA), neutralizing antibody assay (Nab), and western blot. Of note, different assays 
used different cut-off points. For example, for HerpeSelect® 1 ELISA, sera with optical density index values ≥ 1.10 
were considered seropositive and <0.90 seronegative, with the rest deemed equivocal38,39. Meanwhile, for 
Euroimmun Anti-HSV-1 ELISA, sera with optical density index values ≥ 1.10 were considered seropositive and 
<0.80 seronegative, with the rest deemed equivocal39,40.
Country’s income was determined based on the World Bank classification41 for the countries for which HSV-1 
seroprevalence data were available: lower-middle-income countries (Egypt, Jordan, Morocco, Pakistan, Palestine, 
Sudan, Syria, and Yemen), upper-middle-income countries (Algeria, Iran, Iraq, and Lebanon), high-income 
countries (Qatar and Saudi Arabia), and mixed for samples including specimens from different countries.
Missing values in the year of data collection variable were imputed using the median of the values generated 
(for studies with data) for the difference between the year of data collection and the year of publication.
Meta-regressions were conducted in Stata/SE version 1342 using the package metareg43.
Quality assessment. There are documented issues with the sensitivity and specificity of HSV-1 diagnostic 
methods44,45. Therefore, an expert advisor, Professor Rhoda Ashley Morrow from the University of Washington, 
was consulted and assessed the quality of each diagnostic method in each identified relevant study. Only studies 
with sufficiently reliable and valid assays were included. Further quality assessment of included studies was con-
ducted as informed by the Cochrane approach for risk of bias (ROB)29 and precision assessment.
Studies’ assessment into low versus high ROB was based on two quality domains: sampling methodology 
(probability-based versus non-probability-based sampling), and response rate (≥80% versus <80%). For 
instance, if probability-based sampling was used in a given study, the study was classified with a low ROB for that 
domain. Studies with missing information for any of the domains were classified as having unclear ROB for that 
specific domain.
Studies were considered as having high (versus low) precision if the number of HSV-1 tested individuals was at 
least 100 participants. For an HSV-1 seroprevalence of 80% and a sample size of 100, the 95% CI is 70.8–87.3%—a 
reasonable 95% CI estimate for an HSV-1 seroprevalence measure.
Results
search results and scope of evidence. Figure 1 shows the process of study selection based on the 
PRISMA guidelines30. A total of 1,552 citations were retrieved (269 through PubMed, 537 through Embase, 
and 746 through national and regional databases). After duplicates’ removal and titles’ and abstracts’ screening, 
130 records were identified as relevant or potentially relevant. Three additional records were identified through 
screening the bibliography of a previously published review for Iran46.
After full text screening, 15 records reporting an HSV-1 seroprevalence in 14 out of the 23 MENA countries 
were deemed relevant. Thirty-nine HSV-1 seroprevalence measures were extracted yielding 85 stratified meas-
ures. No HSV-1 seroprevalence measures (fulfilling the inclusion criteria) were identified among clinical children 
populations.
Although we searched for records that reported the proportion of GUD or genital herpes attributable to HSV-
1, no such records were identified.
HSV-1 seroprevalence overview. Table 1 summarizes the included HSV-1 seroprevalence measures. 
Studies included were published starting the year 1986, with the majority being cross-sectional in design and 
based on convenience sampling methods.
Stratified HSV-1 seroprevalence measures (number of studies (n) = 85) varied across studies and ranged 
between 23.5–100% with a median of 90.3% (Table 2). The 11 seroprevalence measures in healthy children pop-
ulations ranged between 23.5–86.4% with a median of 69.4%. The 49 seroprevalence measures in healthy adult 
populations ranged between 33.3–100% with a median of 90.7%. The 9 seroprevalence measures in clinical adult 
populations ranged between 60.8–100% with a median of 96.9%.
pooled mean seroprevalence estimates. Table 2 summarizes the results of the meta-analyses. In healthy 
general populations, the pooled mean HSV-1 seroprevalence was 65.2% (95% CI: 53.6–76.1%) for children, and 
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89.4% (95% CI: 87.3–91.4%) for adults. In adult clinical populations, the pooled mean HSV-1 seroprevalence 
was 95.3% (95% CI: 83.9–100%). Among other populations, the pooled mean HSV-1 seroprevalence was 95.2% 
(95% CI: 75.4–100%) in female sex workers, and 97.5% (95% CI: 93.5–99.7%) in mixed health-status populations.
By age group, the pooled mean HSV-1 seroprevalence was lowest at 60.5% (95% CI: 48.1–72.3%) in those aged 
<10 years, followed by 85.6% (95% CI: 80.5–90.1%) in those aged 10–19 years, 90.7% (95% CI: 84.7–95.5%) in 
those aged 20–29 years, and 94.3% (95% CI: 89.5–97.9%) in those aged ≥30 years. The sensitivity analyses using 
GLMM methods produced similar results (Supplementary Table S2).
Evidence of heterogeneity in seroprevalence was present in nearly all meta-analyses (p < 0.0001; Table 2). The 
I² measure indicated that most variation was attributed to true variability in seroprevalence across studies. The 
prediction intervals confirmed the considerable variation in seroprevalence across studies.
Forest plots of meta-analyses can be found in Supplementary Fig. S1.
predictors of seroprevalence and sources of between-study heterogeneity. Table 3 summarizes 
the results of the univariable and multivariable meta-regression models. In the univariable analyses, age bracket, 
age group, country’s income, population type, and sampling method had a p-value < 0.1 and were included in 
the multivariable analyses. Age bracket alone explained 44.3% of the variation in seroprevalence, followed by 
age group at 28.7%. Each of assay type, sample size, sex, year of data collection, and year of publication was not 
significantly associated with HSV-1 seroprevalence.
To account for the fact that age bracket and age group both measure age, two final multivariable models were 
conducted. The first model included age bracket, country’s income, population type, and sampling method. This 
model explained 48.6% of seroprevalence variation. HSV-1 seroprevalence in adults was 1.3-fold (95% CI: 1.2–
1.5) higher than in children. Seroprevalence in upper-middle-income countries and high-income countries was, 
in both, 0.9-fold (95% CI: 0.8–1.0) lower than in lower-middle-income countries. No association with population 
type and sampling method was found.
The second model included age group, assay type, country’s income, population type, and sampling method. 
The model explained 40.2% of seroprevalence variation, with similar results for country’s income, population 
Figure 1. Flow chart of article selection for the systematic review of herpes simplex virus type 1 (HSV-1) in the 
Middle East and North Africa, as adapted from the PRISMA 2009 guidelines30. Abbreviations: HSV-1 = Herpes 
simplex virus type 1, MENA = Middle East and North Africa.
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Author, year
Year(s) 
of data 
collection Country Study site
Study 
design
Sampling 
method Population
HSV-1 
serological 
assay
Sample 
size
HSV-1 
seroprevalence (%)
Healthy children populations (n = 21)
Cowan, 200353 1998–00 Morocco Outpatient clinic CS Conv 1–4 years old children ELISA 159b 55.2
Cowan, 200353 1998–00 Morocco Outpatient clinic CS Conv 5–9 years old children ELISA 159b 80.5
Cowan, 200353 1998–00 Morocco Outpatient clinic CS Conv 10–14 years old children ELISA 160b 86.4
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv 1–5 years old males ELISA 55 60.0
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv 6–10 years old males ELISA 59 74.5
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv 1–5 years old females ELISA 46 50.0
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv 6–10 years old females ELISA 58 81.1
Meguenni, 198955 — Algeria Community CS Conv 6 months-2 years old infants Nab 34 23.5
Meguenni, 198955 — Algeria Community CS Conv 3–5 years old children Nab 33 39.4
Meguenni, 198955 — Algeria Community CS Conv 6–10 years old children Nab 36 69.4
Meguenni, 198955 — Algeria Community CS Conv 11–15 years old children Nab 32 81.3
Healthy adult populations (n = 60)
Ahmed, 199556 — Pakistan Outpatient clinic CSa Conv Healthy controls EIA 56 73.2
Hossain, 198657 — KSA Outpatient clinic CS Conv Pregnant women IFA 1,186 92.0
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv 21–30 years old males ELISA 48 85.4
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv >30 years old males ELISA 86 94.1
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv 21–30 years old females ELISA 68 88.2
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv >30 years old females ELISA 43 95.3
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv Pregnant women ELISA 55 100
Jafarzadeh, 201158 2007–08 Iran Hospital CS Conv >40 years old blood donors ELISA 60 33.3
Meguenni, 198955 — Algeria Community CS Conv 16–20 years old adults Nab 32 87.5
Meguenni, 198955 — Algeria Community CS Conv 21–30 years old adults Nab 32 96.9
Meguenni, 198955 — Algeria Community CS Conv 31–40 years old adults Nab 30 100
Meguenni, 198955 — Algeria Community CS Conv >40 years old adults Nab 35 100
Memish, 201559 2012–13 KSA Outpatient clinic CS RS Healthy females ELISA 2,157 90.9
Memish, 201559 2012–13 KSA Outpatient clinic CS RS Healthy males ELISA 2,828 87.1
Nabipour, 200660 2004-04 Iran Community CS Cluster RS Healthy males ELISA 881 83.8
Nabipour, 200660 2003–04 Iran Community CS Cluster RS Healthy female ELISA 910 88.6
Nasrallah, 201847 2013–16 Mixed Outpatient clinic CS Conv Female blood donors ELISA 88 84.1
Nasrallah, 201847 2013–16 Pakistan Outpatient clinic CS RS Blood donor Pakistani males ELISA 200 77.0
Nasrallah, 201847 2013–16 Iran Outpatient clinic CS Conv Blood donor Iranian males ELISA 113 81.4
Nasrallah, 201847 2013–16 Sudan Outpatient clinic CS Conv Blood donor Sudanese males ELISA 129 90.7
Nasrallah, 201847 2013–16 Yemen Outpatient clinic CS Conv Blood donor Yemeni males ELISA 148 92.6
Nasrallah, 201847 2013–16 Egypt Outpatient clinic CS Conv ≤24 years old blood donor Egyptians males ELISA 50 92.0
Nasrallah, 201847 2013–16 Egypt Outpatient clinic CS Conv 25–29 years old blood donor Egyptians males ELISA 50 100
Nasrallah, 201847 2013–16 Egypt Outpatient clinic CS Conv 30–34 years old blood donor Egyptians males ELISA 50 98.0
Nasrallah, 201847 2013–16 Egypt Outpatient clinic CS Conv 35–39 years old blood donor Egyptians males ELISA 50 98.0
Nasrallah, 201847 2013–16 Egypt Outpatient clinic CS Conv 40–44 years old blood donor Egyptians males ELISA 50 98.0
Nasrallah, 201847 2013–16 Egypt Outpatient clinic CS Conv 45–49 years old blood donor Egyptians males ELISA 50 100
Nasrallah, 201847 2013–16 Egypt Outpatient clinic CS Conv 50–54 years old blood donor Egyptians males ELISA 39 94.9
Nasrallah, 201847 2013–16 Egypt Outpatient clinic CS Conv ≥55 years old blood donor Egyptians males ELISA 19 100
Nasrallah, 201847 2013–16 Qatar Outpatient clinic CS Conv ≤24 years old blood donor Qatari males ELISA 50 70.0
Nasrallah, 201847 2013–16 Qatar Outpatient clinic CS Conv 25–29 years old blood donor Qatari males ELISA 50 62.0
Nasrallah, 201847 2013–16 Qatar Outpatient clinic CS Conv 30–34 years old blood donor Qatari males ELISA 50 80.0
Nasrallah, 201847 2013–16 Qatar Outpatient clinic CS Conv 35–39 years old blood donor Qatari males ELISA 50 82.0
Nasrallah, 201847 2013–16 Qatar Outpatient clinic CS Conv 40–44 years old blood donor Qatari males ELISA 50 84.0
Nasrallah, 201847 2013–16 Qatar Outpatient clinic CS Conv 45–49 years old blood donor Qatari males ELISA 50 96.0
Nasrallah, 201847 2013–16 Qatar Outpatient clinic CS Conv 50–54 years old blood donor Qatari males ELISA 50 92.0
Nasrallah, 201847 2013–16 Qatar Outpatient clinic CS Conv ≥55 years old blood donor Qatari males ELISA 50 92.0
Nasrallah, 201847 2013–16 Jordan Outpatient clinic CS Conv Blood donor Jordanian males ELISA 200 86.5
Nasrallah, 201847 2013–16 Palestine Outpatient clinic CS Conv Blood donor Palestinians males ELISA 200 80.5
Nasrallah, 201847 2013–16 Syria Outpatient clinic CS Conv Blood donor Syrian males ELISA 200 88.5
Nasrallah, 201847 2013–16 Lebanon Outpatient clinic CS Conv Blood donor Lebanese males ELISA 118 81.4
Obeid, 200761 2004–04 KSA Hospital CS Conv Pregnant women ELISA 459 84.1
Continued
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type, and sampling method as in the first model. Compared to HSV-1 seroprevalence in those <10 years old, 
seroprevalence was 1.3-fold (95% CI: 1.1–1.6) higher in those 10–19 years old, 1.4-fold (95% CI: 1.2–1.7) higher 
in those 20–29 years old, and 1.5-fold (95% CI: 1.3–1.7) higher in those ≥30 years old.
Quality assessment. Out of 32 records that included seroprevalence measures, only 15 were included in the 
systematic review with the remaining 17 being excluded due to potential issues in the validity of the diagnostic 
method, such as potential cross-reactivity with HSV-2 antibodies (Fig. 1). Of the studies included, 64.1% had high 
precision, 7.7% had low ROB for the sampling methodology domain, and 48.7% had low ROB for the response 
rate domain. These results, in context of the meta-regression models results, with different factors including sam-
ple size, sampling method, and assay type not being predictors of HSV-1 seroprevalence, suggest that overall the 
studies had reasonable quality.
Author, year
Year(s) 
of data 
collection Country Study site
Study 
design
Sampling 
method Population
HSV-1 
serological 
assay
Sample 
size
HSV-1 
seroprevalence (%)
Patnaik, 200762 — Morocco Hospital CS Conv Pregnant women WB 169 98.8
Pourmand, 200963 — Iran Outpatient clinic CS Conv Pregnant women ELISA 65 55.4
Ziyaeyan, 200764 — Iran Hospital CS Conv 16–20 years old pregnant women Nab 104 83.6
Ziyaeyan, 200764 — Iran Hospital CS Conv 21–25 years old pregnant women Nab 125 94.4
Ziyaeyan, 200764 — Iran Hospital CS Conv 26–30 years old pregnant women Nab 113 90.3
Ziyaeyan, 200764 — Iran Hospital CS Conv 31–35 years old pregnant women Nab 44 95.4
Ziyaeyan, 200764 — Iran Hospital CS Conv 36–40 years old pregnant women Nab 14 100
Healthy age-mixed populations (n = 5)
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv 11–20 years old males ELISA 57 77.1
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv 11–20 years old females ELISA 134 83.6
RezaeiC, 201265 2010–11 Iran Outpatient clinic CS Cluster RS Healthy population ELISA 800 58.4
RezaeiC, 201266 2010–11 Iran Outpatient clinic CS Cluster RS <85 years old patients ELISA 200 65.5
Clinical adult populations (n = 20)
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv Patients with labials herpes ELISA 36 100
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv Patients with atherosclerosis ELISA 60 100
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv Kidney transplant patients ELISA 32 96.9
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv Patients with herpetic keratitis ELISA 14 85.7
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv Patients with STDs ELISA 21 90.5
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv Patients with cervical cancer ELISA 51 100
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv HIV positive patients ELISA 25 96.0
Jafarzadeh, 201158 2007–08 Iran Hospital CS Conv Patients with myocardial infarction ELISA 120 60.8
Janier, 199967 1994–94 Mixed Outpatient clinic CS Conv Patients with STDs EIA 99 98.9
Clinical age-mixed population (n = 4)
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv Patients with encephalitis ELISA 51 58.8
Ibrahim, 200054 1995–98 Syria Outpatient clinic CS Conv Patients with meningitis ELISA 21 85.7
Other populations (n = 10)
Cowan, 200353 1998–00 Morocco Outpatient clinic CS Conv 15–19 years old healthy and HIV infected adults ELISA 494b 92.2
Cowan, 200353 1998–00 Morocco Outpatient clinic CS Conv 20–29 years old healthy and HIV infected adults ELISA 494b 92.1
Cowan, 200353 1998–00 Morocco Outpatient clinic CS Conv 30–34 years old healthy and HIV infected adults ELISA 494b 95.0
Cowan, 200353 1998–00 Morocco Outpatient clinic CS Conv 35–39 years old healthy and HIV infected adults ELISA 494b 98.8
Cowan, 200353 1998–00 Morocco Outpatient clinic CS Conv 40–45 years old healthy and HIV infected adults ELISA 494b 100
Cowan, 200353 1998–00 Morocco Outpatient clinic CS Conv >45 years old healthy and HIV infected adults ELISA 493b 100
Ibrahim, 200054 1995–98 Syria Community CS Conv Female sex workers ELISA 54 100
Ibrahim, 200054 1995–99 Syria Community CS Conv Female sex workers ELISA 47 100
Ibrahim, 200054 1995–100 Syria Community CS Conv Arab bar-girls ELISA 50 98.0
Ibrahim, 200054 1995–101 Syria Community CS Conv Foreign bar-girls ELISA 75 92.0
Table 1. Studies reporting herpes simplex virus type 1 (HSV-1) seroprevalence in the Middle East and 
North Africa. aActual study design was cohort but the extracted seroprevalence measure was for the baseline 
measurement. bStudy included overall sample size, but no individual strata sample sizes. Each stratum sample 
size was assumed equal to overall sample size divided by the number of strata in the study. Abbreviations: 
Conv = Convenience, CS = Cross-sectional, EIA = Enzyme immunoassay, ELISA = Enzyme-linked 
immunosorbent assay, HIV = Human immunodeficiency virus, HSV-1 = Herpes simplex virus type 1, 
IFA = Indirect fluorescent assay, KSA = Kingdom of Saudi Arabia, Nab = Neutralization test with neutralizing 
antibody, RS = Random sampling, STD = Sexually transmitted disease, TORCH = Toxoplasmosis, other 
(syphilis, varicella-zoster, parvovirus B19), rubella, cytomegalovirus, and herpes infections, WB = Western blot.
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The detailed quality assessment of included studies can be found in Supplementary Table S3.
Discussion
HSV-1 epidemiology in MENA was investigated through a comprehensive systematic review and meta-analytics 
of existing evidence. HSV-1 seroprevalence was found at high level, suggesting considerable HSV-1-related mor-
bidity that is yet to be quantified and tackled. Sixty-five percent of children and 90% of adults were found seropos-
itive—seroprevalence increased rapidly with age at younger ages, and was consistent with most infections being 
acquired in childhood.
Remarkably, about half of the observed variation in seroprevalence was explained by factors set a priori and 
examined in this study. Age alone explained 44.3% of the variation. Despite improvements in socio-economic 
conditions and earlier speculation that seroprevalence levels may have been declining in MENA47, we did not find 
evidence for a declining trend over the last two decades. We also did not find evidence for variation in seroprev-
alence by sex, population type (healthy versus clinical), or study characteristics including assay type, sampling 
method, and sample size.
Though there was no evidence for recent declines in seroprevalence, youth had considerably lower HSV-1 
seroprevalence than older subjects. As much as one-third of youth in MENA may be reaching sexual debut unin-
fected and thus potentially at risk of sexual acquisition, in context of recent evidence from Western countries and 
Asia reporting an increase in incidence of genital herpes attributed to HSV-1 rather than HSV-26,21–26. We did 
not, nonetheless, identify any evidence for a potential role for HSV-1 sexual transmission in MENA. Despite the 
extensive search in multiple international, regional, and national databases, we failed to identify a single study 
that assessed the etiological role of HSV-1 in GUD or genital herpes in this region.
A comparison of the findings of the present study with that of a recent systematic review of HSV-1 in Asia21 
demonstrates key insights about what may be general (or somewhat general) patterns in the global epidemi-
ology of HSV-1 infection. Age in both systematic reviews was by far the strongest predictor of HSV-1 sero-
prevalence. Remarkably, in both MENA and Asia, seroprevalence in children was assessed at about 60%, and 
seroprevalence among adults was about 30% higher than that in children. Country’s income was also a predictor 
Population type
Studies Samples HSV-1 seroprevalence
Pooled mean HSV-1 
seroprevalence Heterogeneity measures
Total N Total n Range Median Mean (95% CI)
Qa  
(p-value)
I²b (%)  
(95% CI)
Prediction 
Intervalc (%)
Healthy general populations
Children 11 831 23.5–86.4 69.4 65.2 (53.6–76.1) 109.2 (p < 0.0001) 90.8 (85.6–94.2) 22.3–97.1
Adults 49 11,754 33.3–100 90.7 89.4 (87.3–91.4) 429.6 (p < 0.0001) 88.8 (86.1–91.0) 74.3–98.6
Age-mixed 4 1,191 58.4–83.6 71.3 71.1 (58.5–82.3) 42.1 (p < 0.0001) 92.9 (85.0–96.6) 13.7–100
All healthy general 
populations 64 13,776 23.5–100 86.5 85.3 (82.3–87.9) 1,107.9 (p < 0.0001) 94.3 (93.2–95.1) 59.4–99.4
Clinical populations
Children — — — — — — — —
Adults 9 458 60.8–100 96.9 95.3 (83.9–100) 114.4 (p < 0.0001) 93.0 (88.9–95.6) 38.1–100
Age-mixed 2 72 58.8–85.7 72.2 66.7 (54.6–77.3) — — —
All clinical 
populations 11 530 58.8–100 96.0 92.3 (80.3–99.4) 147.1 (p < 0.0001) 93.2 (89.7–95.5) 33.7–100
Other populations
Female sex workers 4 226 92.0–100 99.0 95.2 (75.4–100) 57.8 (p < 0.0001) 94.8 (89.7–97.4) 0.0–100
Healthy/clinical 
adult populations 6 2,963 92.1–100 96.9 97.5 (93.5–99.7) 151.4 (p < 0.0001) 96.7 (94.7–97.9) 74.8–100
Age group
<10 years 9 639 23.5–81.1 60.0 60.5 (48.1–72.3) 73.6 (p < 0.0001) 89.1 (81.6–93.6) 18.4–95.0
10–19 years 7 1,013 77.1–92.2 83.6 85.6 (80.5–90.1) 20.5 (p = 0.0023) 70.7 (36.0–86.6) 68.5–96.9
20–29 years 8 980 62.0–100 91.2 90.7 (84.7–95.5) 43.8 (p < 0.0001) 84.0 (70.2–91.4) 66.2–100
≥30 years 24 2,965 33.3–100 95.7 94.3 (89.5–97.9) 433.2 (p < 0.001) 94.7 (93.2–95.9) 60.9–100
All children 11 831 23.5–86.4 69.4 65.2 (53.6–76.1) 109.2 (p < 0.0001) 90.8 (85.6–94.2) 22.3–97.1
All adults 68 15,401 33.3–100 92.0 91.8 (89.6–93.7) 1,087 (p < 0.0001) 93.8 (92.8–94.7) 71.0–100
All age-mixed 6 1,263 58.4–85.7 71.3 71.1 (60.7–80.6) 47.5 (p < 0.0001) 89.5 (79.7–94.5) 34.2–96.8
All studies 85 17,495 23.5–100 90.3 88.0 (85.3–90.5) 1,973.8 (p < 0.0001) 95.7 (95.2–96.2) 58.4–100
Table 2. Pooled mean estimates for herpes simplex virus type 1 (HSV-1) seroprevalence in different 
populations in the Middle East and North Africa. aQ: The Cochran’s Q statistic is a measure used here to assess 
the existence of heterogeneity in seroprevalence measures across studies. bI2: A measure used here to assess the 
magnitude of between-study variation that is due to actual differences in seroprevalence across studies rather 
than chance. cPrediction interval: A measure used here to estimate the distribution (the 95% interval) of true 
seroprevalence around the estimated pooled mean. Abbreviations: CI = Confidence interval, HSV-1 = Herpes 
simplex virus type 1.
www.nature.com/scientificreports/
8Scientific RepoRts |          (2019) 9:1136  | https://doi.org/10.1038/s41598-018-37833-8
of seroprevalence with higher income associated with lower seroprevalence, attesting to an apparently global 
association between HSV-1 infection and socio-economic status11,48. However, the association of HSV-1 and 
socio-economic status differed between the two regions. In MENA, lower-middle-income countries had the high-
est seroprevalence, whereas in Asia, upper-middle-income countries had the highest seroprevalence. Possibly, the 
rapid modernization of Asia compared to MENA may contribute to explaining this difference.
In both MENA and Asia, sex, population type, assay type, sample size, and sampling method were not associ-
ated with HSV-1 seroprevalence. This suggests that HSV-1 is a truly general population infection that permeates 
all strata of society—there is no difficulty in sampling a representative sample provided the age distribution is 
representative. In both regions also, no evidence for a temporal trend in seroprevalence was identified despite 
the evidence for temporal declines in seroprevalence in Western countries11,13–20. Notably in MENA, half of the 
variation in seroprevalence (49%) was explained by the a priori considered factors, but only 26% of the variation 
was explained in Asia by the same considered factors21. The latter finding may relate to a higher population heter-
ogeneity across countries in Asia than in MENA.
Our review and meta-analytics are limited by the quantity, quality, and representativeness of included studies. 
No data were identified for nine (mostly non-populous) of the 23 MENA countries, thereby potentially affecting 
the generalizability of the analyses to all of MENA. The number of seroprevalence measures varied from each 
study to another—only one (large) study, for example, contributed 29% of all stratified seroprevalence measures47. 
The majority of studies used convenience sampling (as opposed to probability-based sampling) of opportunistic 
Studies Samples Univariable analysis Multivariable analysis
Total N Total n RR (95% CI) p-value
Variance 
explained 
adjusted R2 (%)
Model 1a Model 2b
ARR (95% CI) p-value ARR (95% CI) p-value
Age bracket
Children 11 831 1.0 — 1.0 — — —
Adults 68 15,401 1.3 (1.2–1.5) 0.000 1.3 (1.2–1.5) 0.000 — —
Age-mixed 6 1,263 1.0 (0.9–1.2) 0.806 44.3 1.0 (0.9–1.2) 0.580 — —
Age group
<10 9 639 1.0 — — — 1.0 —
10–19 7 1,013 1.3 (1.1–1.6) 0.003 — — 1.3 (1.1–1.6) 0.002
20–29 8 980 1.4 (1.2–1.6) 0.000 — — 1.4 (1.2–1.7) 0.000
≥30 24 2,965 1.4 (1.2–1.6) 0.000 — — 1.5 (1.3–1.7) 0.000
Mixed 37 11,898 1.3 (1.2–1.5) 0.000 28.7 — — 1.4 (1.2–1.6) 0.000
Assay type
ELISA 68 15,321 1.0 — — — — —
EIA 2 155 1.0 (0.8–1.3) 0.915 — — — —
Nab 13 664 1.0 (0.9–1.1) 0.826 — — — —
IFA 1 1,186 1.1 (0.7–1.6) 0.687 — — — —
Western blot 1 169 1.1 (0.8–1.7) 0.434 0.0 — — — —
Country’s income
LMIC 49 6,347 1.0 — 1.0 — 1.0 —
UMIC 22 3,931 0.9 (0.8–1.0) 0.016 0.9 (0.8–1.0) 0.044 0.8 (0.8–1.0) 0.044
HIC 12 7,030 0.9 (0.8–1.1) 0.440 0.9 (0.8–1.0) 0.076 0.9 (0.8–1.0) 0.101
Mixed 2 187 1.0 (0.8–1.3) 0.822 3.3 1.0 (0.8–1.2) 0.847 1.0 (0.8–1.2) 0.848
Population type
Healthy general 
populations 64 13,776 1.0 — 1.0 — 1.0 —
Clinical populations 11 530 1.0 (0.9–1.2) 0.355 1.0 (0.9–1.1) 0.967 1.0 (0.9–1.1) 0.987
Other populations 10 3,189 1.1 (1.0–1.3) 0.064 4.6 1.0 (0.9–1.1) 0.839 1.0 (0.9–1.1) 0.706
Sample sizec
<100 14 679 1.0 — — — — —
≥100 71 16,816 1.0 (0.9–1.1) 0.712 0.0 — — — —
Sampling method
Non-probability-based 81 14,704 1.0 — 1.0 — 1.0 —
Probability based 4 2,791 0.8 (0.7–1.0) 0.070 9.3 0.9 (0.8–1.1) 0.621 0.9 (0.7–1.1) 0.251
Sex
Female 23 6,115 1.0 — — — — —
Male 31 6,080 1.0 (0.9–1.1) 0.713 — — — —
Mixed 31 5,300 0.9 (0.8–1.0) 0.210 0.0 — — — —
Year of data collection 85 17,495 1.0 (1.0–1.0) 0.993 0.0 — — — — —
Year of publication 85 17,495 1.0 (1.0–1.0) 0.911 0.0 — — — — —
Table 3. Univariable and multivariable meta-regression analyses for herpes simplex virus type 1 (HSV-1) 
seroprevalence in the Middle East and North Africa. aVariance explained by the final multivariable model 
1 (adjusted R2) = 48.6%. bVariance explained by the final multivariable model 2 (adjusted R2) = 40.2%. 
cSample size denotes the sample size of the study population found in the original publication. Abbreviations: 
ARR = Adjusted relative risk, CI = Confidence interval, EIA = Enzyme immunoassay, ELISA = Enzyme-
linked immunosorbent type-specific assay, HIC = High-income country, IFA = Immunofluorescence assay, 
LMIC = Lower-middle-income country, Nab = Neutralizing antibody assay, RR = Relative risk, UMIC = Upper-
middle-income country.
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populations such as blood donors or outpatients (Table 1). The latter, though, may not have been a limitation in 
context of the findings of the meta-regression analyses (Table 3).
Studies used different diagnostic methods, and such methods may differ in sensitivity and specificity44,45. 
Presence of HSV-2 antibodies may also affect diagnostic methods differentially, particularly the classic 
“relative-reactivity” methods such as IFA and Nab49–51. This limitation, however, may not have affected our results, 
as HSV-2 infection has a low seroprevalence in MENA52, and earlier work suggests minimal impact of this lim-
itation on specifically HSV-1 seroprevalence (as opposed to HSV-2 seroprevalence)49–51. The meta-regression 
analyses found no variations in HSV-1 seroprevalence across assay types (Table 3).
There was extensive heterogeneity in HSV-1 seroprevalence measures, but half of this heterogeneity was sub-
sequently explained by only two factors, age and country’s income (Table 3). Lastly, no study of HSV-1 viral detec-
tion in GUD or in genital herpes in MENA was identified, thus limiting our ability to assess the epidemiological 
role of HSV-1 sexual transmission. In spite of these limitations, our study is the first to draw a comprehensive 
synthesis and analytics of HSV-1 seroprevalence for the MENA region, and to highlight opportunities for related 
research and public health response.
Conclusions
HSV-1 seroprevalence in MENA indicated that 65% of children and 90% of adults had been exposed to this 
infection, by inference, most often during childhood. Age and country’s income were the strongest predictors 
of HSV-1 seroprevalence and explained half of seroprevalence variation. No evidence was found for a temporal 
trend in seroprevalence over the last two decades despite improvements in socio-economic conditions. With no 
identified study of HSV-1 viral detection in GUD or in genital herpes, the role of HSV-1 sexual transmission in 
MENA remains unknown. This lack of data calls for at least basic or opportunistic GUD/genital herpes etiological 
surveillance. The totality of the findings highlights the timeliness of accelerating HSV-1 vaccine development to 
control one of the most endemic infections worldwide.
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